Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7771950 versus tucatinib with trastuzumab + capecitabine in pretreated HER2-positive advanced or metastatic breast cancer
2025-524498-17-00Phase 3Authorised
- Sponsor
- Roche
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of RO7771950 in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-Free Survival in Full Analysis Set. Planned start May 2026; status: authorised.
02
Drugs
RO7771950
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-524498-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524498-17-00.